- Home
- KPRX
KPRX
Kiora Pharmaceuticals Inc.
as 03-24-2025 4:00pm EST
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ENCINITAS |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 12.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.91 - $6.48 | Next Earning Date: | 05-09-2025 |
| Revenue: | $16,020,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -82.10% |
Latest Kiora Pharmaceuticals Inc. News
KPRX Breaking Stock News: Dive into KPRX Ticker-Specific Updates for Smart Investing
Newsfile
13 days ago
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
Newsfile
a month ago
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Newsfile
a month ago
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
Simply Wall St.
4 months ago
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative
Newsfile
5 months ago
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
TipRanks
5 months ago
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
Newsfile
5 months ago
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
Newsfile
6 months ago
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Compare KPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KPRX Kiora Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.